Vemurafenib induces senescence in acute myeloid leukemia and myelodysplastic syndrome by activating the HIPPO signaling pathway: implications for potential targeted therapy

Abstract Background The outcome of Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) remain dismal despite the development of treatment. Targeted therapy is gaining more and more attention in improving prognosis. Methods Expression of BRAF was analyzed by RT-qPCR in AML and MDS patient...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Qiao Zhou, Jiamin Zhang, Jingsong Zhang, Simin Liang, Duo Cai, Han Xiao, Yu Zhu, Wenqiong Xiang, Fernando Rodrigues-Lima, Jianxiang Chi, Fabien Guidez, Li Wang
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	BMC 2024-01-01
Rangatū:	Biology Direct
Ngā marau:	BRAF Vemurafenib Senescence HIPPO signaling pathway MDS AML
Urunga tuihono:	https://doi.org/10.1186/s13062-023-00451-0
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!